AXIM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AXIM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
AXIM Biotechnologies has the GF Value Rank of 0.
GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.
GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).
We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.
After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.
A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Thank you for viewing the detailed overview of AXIM Biotechnologies's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Kurt Phinney | officer: Chief Operating Officer | 6914 MAGELLAN WAY, SARASOTA FL 34243 |
Peter O'rourke | director | C/O NORTHVIEW ACQUISITION CORP., 207 WEST 25TH STREET, 9TH FLOOR, NEW YORK NY 10001 |
Catalina Valencia | 10 percent owner | 6191 CORNERSTONE COURT, E, SUITE 114, SAN DIEGO CA 92121 |
Glycodots, Llc | 10 percent owner | 6191 CORNERSTONE COURT, E, SUITE 114, SAN DIEGO CA 92121 |
Juniper & Ivy Corp | 10 percent owner | 5201 MEMORIAL DRIVE, SUITE 616, HOUSTON TX 77007 |
Huemoeller John Walter Ii | director | 305 SAN ANSELMO AVENUE, SUITE 300, SAN ANSELMO CA 94960 |
Blake Schroeder | director | 5 ROCKERFELLER PLACE, 20TH FLOOR, SUITE 83, NEW YORK NY 10111 |
Robert L Cunningham | director | 5 ROCKERFELLER PLACE, 20TH FLOOR, SUITE 83, NEW YORK NY 10111 |
Timothy Richard Scott | director | 5 ROCKERFELLER PLACE, 20TH FLOOR, SUITE 83, NEW YORK NY 10111 |
Robert Malasek | officer: CFO | PO BOX 235472, ENCINITAS CA 92023 |
Lekhram Changoer | 10 percent owner | 18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022 |
Medical Marijuana, Inc. | 10 percent owner | 12255 CROSTHWAITE CIRCLE, POWAY CA 92064 |
Van Damme Philip A | 10 percent owner | 18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022 |
Foundation Sanammad | 10 percent owner | 18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022 |
George Anastassov | 10 percent owner | 18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 07-02-2022
By PurpleRose PurpleRose • 07-13-2022
By Stock market mentor Stock market mentor • 01-17-2023
By GuruFocusNews GuruFocusNews • 06-19-2022
By GuruFocusNews GuruFocusNews • 06-22-2022
By GuruFocusNews GuruFocusNews • 06-02-2022
By GuruFocusNews GuruFocusNews • 06-23-2022
By GuruFocusNews GuruFocusNews • 05-10-2022
By GuruFocusNews GuruFocusNews • 06-03-2022
By PurpleRose PurpleRose • 07-21-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.